Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor  by Beije, Nick et al.
www.neoplasia.com
Volume 18 Number 11 November 2016 pp. 647–653 647
Abbreviati
epidermal
progression
Address a
Rotterdam
E-mail: n.b
1 This wo
grant nuPrognostic Impact of HER2 and ER
Status of Circulating Tumor Cells in
Metastatic Breast Cancer Patients
with a HER2-Negative Primary
Tumor1ons: CTC, circulating tumor cell; ER, estrogen receptor; HER2, human
growth factor receptor 2; MBC, metastatic breast cancer; PFR6months,
-free-rate after 6 months; PT, primary tumor
ll correspondence to: Nick Beije, MD, Wytemaweg 80, 3015 CN,
, The Netherlands.
eije@erasmusmc.nl
rk was supported by KWF (Netherlands Cancer Foundation;
mber EMCR 2012-5390) and by Janssen Diagnostics. JanssenNick Beije*, Wendy Onstenk*, Jaco Kraan*,
Anieta M. Sieuwerts*, Paul Hamberg†, Luc Y. Dirix‡,
Anja Brouwer‡, Felix E. de Jongh§, Agnes Jager*,
Caroline M. Seynaeve*, Ngoc M. Van*,
John A. Foekens*, John W.M. Martens* and
Stefan Sleijfer*
*Erasmus MC Cancer Institute, Erasmus University Medical
Center, Department of Medical Oncology and Cancer
Genomics Netherlands, Wytemaweg 80, 3015 CN, Rotter-
dam, The Netherlands; †Franciscus Gasthuis, Department of
Internal Medicine, Kleiweg 500, 3045 PM, Rotterdam, The
Netherlands; ‡Oncology Center GZA Hospitals Sint Augus-
tinus, Translational Cancer Research Unit, Department of
Medical Oncology, Oosterveldlaan 26, 2610, Antwerp,
Belgium; §Ikazia Hospital, Department of Internal Medicine,
Montessoriweg 1, 3083 AN, Rotterdam, The NetherlandsAbstract
BACKGROUND: Preclinical and clinical studies have reported that human epidermal growth factor receptor 2
(HER2) overexpression yields resistance to endocrine therapies. Here the prevalence and prognostic impact of
HER2-positive circulating tumor cells (CTCs) were investigated retrospectively in metastatic breast cancer (MBC)
patients with a HER2-negative primary tumor receiving endocrine therapy. Additionally, the prevalence and
prognostic significance of HER2-positive CTCs were explored in a chemotherapy cohort, as well as the prognostic
impact of the estrogen receptor (ER) CTC status in both cohorts. METHODS: Included were MBC patients with a
HER2-negative primary tumor, with ≥1 detectable CTC, starting a new line of treatment. CTCs were enumerated
using the CellSearch system, characterized for HER2 with the CellSearch anti-HER2 phenotyping reagent, and
characterized for ER mRNA expression. Primary end point was progression-free rate after 6 months (PFR6months)
of endocrine treatment in HER2-positive versus HER2-negative CTC patients. RESULTS: HER2-positive CTCs were
present in 29% of all patients. In the endocrine cohort (n = 72), the PFR6months was 53% for HER2-positive
versus 68% for HER2-negative CTC patients (P = .23). In the chemotherapy cohort (n = 82), no prognostic value
of HER2-positive CTCs on PFR6months was observed either. Discordances in ER status between the primary
tumor and CTCs occurred in 25% of all patients but had no prognostic value in exploratory survival analyses.
CONCLUSION: Discordances regarding HER2 status and ER status between CTCs and the primary tumor occurred
frequently but had no prognostic impact in our MBC patient cohorts.
Neoplasia (2016) 18, 647–653Diagnostics did not play any role in the design, analysis, and/or interpretation of the
presented data.
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Treatment of metastatic breast cancer (MBC) is currently mainly
driven by the characteristics of the primary tumor (PT). However,
clinically relevant discordances between the PT and the metastases
with respect to the estrogen receptor (ER) status and the human
epidermal growth factor receptor 2 (HER2) status occur and
influence systemic therapy choices and patient management [1]. As
a result, both European and American guidelines [2,3] recommend to
perform biopsies of metastatic lesions to assess their receptor status
and decide on subsequent systemic therapy. Biopsies of metastases
are, however, often not performed because this is regarded as a
cumbersome procedure for patients, and it is sometimes even
impossible due to inaccessibility of the metastases. Another limitation
of taking single metastatic biopsies is that intratumor and intermeta-
static heterogeneity is missed. To assess the characteristics of
metastatic tumor cells in a minimally invasive way, it is attractive to
obtain circulating tumor cells (CTCs) as a liquid biopsy from
peripheral blood. Discrepancies between the ER status and the HER2
status of the PT and the CTCs in MBC have been demonstrated by
numerous groups [4–18]. Some of these groups have also reported on
the prognostic value of receptor discrepancies between PTs and
CTCs, but such reports have been scarce [17,18]. Further, previous
studies have been performed in rather small and heterogeneous
groups of patients, making it difficult to draw firm conclusions on the
exact clinical relevance of ER and HER2 expression in CTCs.
It has been suggested that the HER2 status of the tumor impacts
response to endocrine therapy. Several preclinical studies demonstrated
that the introduction of the HER2 transcript in ER-positive breast cancer
cell lines confers endocrine resistance [19–21]. In addition, ameta-analysis
in 2379 MBC patients demonstrated that patients with a HER2-positive
PT were less sensitive to endocrine treatment than patients with a
HER2-negative PT [22]. In the current study, we investigated whether or
notMBC patients with a HER2-negative PT, but HER2-positive CTCs,
have a worse outcome to endocrine treatment compared with patients
with HER2-negative CTCs. In addition, a separate control group of
MBC patients with a HER2-negative PT receiving first-line chemother-
apywas included inwhich the prognostic impact ofHER2-positiveCTCs
was explored. Also explored in both cohorts were the clinical impact of
switches in ER expression between the PT and CTCs.
Methods
Patients and Treatment
MBC patients with a HER2-negative PT and the presence of at least
one detectable CTC by the CellSearch system (see below), who started a
new line of systemic treatment forMBC,were eligible for this study.We
used data from our CTC studies with patients starting first-line
chemotherapy (study 06-248 [9,17,23]) or starting a new line of
endocrine therapy (study 09-405 [24]) for MBC. All patients had been
included between February 2008 and March 2015 in six centers in the
Netherlands and Belgium. From all patients, 2 × 7.5 mL of blood was
drawn for CTC enumeration and CTC characterization. The local
institutional review board of each participating center approved the
study protocols (Erasmus MC ID MEC-06-248 and MEC-09-405).
All patients provided written informed consent.
Enumeration of CTCs and HER2 Staining
Before the start of a new line of systemic treatment for MBC,
7.5 ml of blood was drawn in CellSave tubes (Janssen Diagnostics,Raritan, NJ). CTC enumerations were performed within 96 hours of
the blood draw using the CellSearch system (Janssen Diagnostics).
CTCs were characterized for HER2 expression directly in the
CellSearch system using the anti-HER2 antibody as described by the
manufacturer (CellSearch tumor phenotyping reagent HER2, Janssen
Diagnostics). We used the cutoff for HER2 positivity in CTCs as
described by Riethdorf and colleagues [25]; a gallery of representative
images for scoring is presented in Supplementary Figure 1. When at
least one CTC immunofluorescently stained 2+ or 3+ for HER2, the
patient was considered as having HER2-positive CTCs. The results of
the enumeration were always checked by a second certified reviewer.
The results of the HER2 staining were reviewed in a HER2 consensus
meeting involving two investigators (N.B. and J.K.).
CTC ER Assay
Simultaneously with the blood draw for CTC enumeration, 7.5 ml
of blood was drawn in EDTA tubes and enriched for CTCs using the
CellSearch profile kit (Janssen Diagnostics). Samples were processed
within 24 hours and subsequently frozen at −80°C for RNA isolation
and analysis. Larger than 200 bp RNA was isolated using the AllPrep
DNA/RNA Micro Kit (Qiagen, Germantown, MD). Generation of
cDNA, preamplification, and reverse transcription quantitative
polymerase chain reaction to quantify the expression of ESR1 were
performed as described in detail before using a validated ESR1
Taqman assay (Hs00174860 m1; Applied Biosystems, San Francisco,
CA) [9]. ER positivity in CTCs was defined as an ESR1 mRNA ΔCq
level higher than −3.89 corrected for background healthy donor blood
signal, which we previously demonstrated to be a reliable cutoff for
ESR1 with excellent sensitivity and specificity [17].
Statistical Considerations
The primary end point of this study was the progression-free rate
after 6 months of treatment (PFR6months) in patients receiving
endocrine therapy. A small survey among medical oncologists
revealed that a PFR6months of 20% for endocrine therapy alone in
MBC patients with HER2-positive CTCs would be convincing
enough for medical oncologist not to treat an MBC patient with an
ER-positive PT with endocrine therapy alone. Given that the
expected PFR6months for endocrine therapy in unselected MBC
patients is around 70% (and certainly not lower than 50%) and the
prevalence of HER2-positive CTCs was expected to be around 25%,
we calculated that 60 patients would render 15 patients with
HER2-positive CTCs to detect a PFR6months of 20% with a 95%
confidence interval (CI) not higher than 50% (4%-48%), with a type
I error probability (α) of .05 and a type II error probability (β) of .2.
Secondary objectives were 1) to explore the association between the
HER2 status of CTCs and the PFR6months on chemotherapy (as a
control cohort), 2) to establish the incidence of ER-positive CTCs in
the endocrine and chemotherapy cohort, 3) to establish discrepancy
rates of the ER and HER2 status in CTCs compared with PT
characteristics in both cohorts, and 4) to explore whether an
ER-status switch between the primary breast tumor and the CTCs
was associated with outcome in both cohorts. The date of progression
was established by the treating physician and was defined as
radiological progression according to Response Evaluation Criteria
In Solid Tumors (RECIST) version 1.1 [26]. In case of poorly
evaluable disease, the treating physician was allowed to use other
techniques considered to be appropriate (e.g., bone scan, serum
biomarkers, CTC counts) to assess progressive disease. Data on the
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Denmark) scoring and the percentage of ER-positive tumor cells] of
the PT were collected from the pathology report. A HER2-negative
PT was defined as having 0 or 1+ scoring according to the HercepTest
(scored according to the manufacturer's instructions) on the PT, or
2+ scoring in combination with negative HER2 in situ hybridization.
An ER-negative PT was defined as having b10% of the primary
tumor cells staining for ER using immunohistochemistry.
Differences in the PFR6months between patients with
HER2-positive versus HER2-negative CTCs were analyzed using
the χ2 test. Univariate Cox regression was used to evaluate whether
the presence of at least one HER2-positive CTC (as a dichotomous
variable) was associated with progression-free survival (PFS) or overall
survival (OS). The HER2/CTC ratio was calculated by dividing the
number of HER2-positive CTCs by the total number of CTCs. No
statistics were performed in the ER-CTC–related analyses, as this
study was not appropriately powered to evaluate the prognostic power
of the ER-CTC status. Instead, Kaplan-Meier curves were construct-
ed to explore the potential prognostic power of the ER-CTC status.
Associations between the HercepTest score and the HER2-CTC
status were investigated with the χ2 test, whereas associations between
the percentage of ER-positive tumor cells in the PT and ER switches
were compared with the Kruskal-Wallis test. Reported P values are
two-sided, and a significance level α = .05 was used. REMARK
criteria [27] were taken into account for this report. Analyses were
done using Stata/SE version 12 (StataCorp LP, College Station, TX).
Results
Patient Characteristics
A total of 154 MBC patients were included in the current analysis
(Table 1); 72 patients were treated with endocrine therapy and 82
patients with first-line chemotherapy for MBC. Patients treated with
endocrine therapy mainly started this as first-line therapy (69%) for
MBC and mostly received an aromatase inhibitor (64%). The
patients in the chemotherapy cohort predominantly received
taxane-based (48%) or anthracycline-based chemotherapy (35%).Table 1. Baseline Characteristics
Endocrine Therapy
(n = 72)
Chemotherapy
(n = 82)
Age at inclusion, median (range) 67 (37-88) 61 (33-85)
Primary tumor ER positive 72 (100%) 57 (70%)
Previous chemotherapy lines for MBC
0 68 (94%) 82 (100%)
1 4 (6%)
Previous endocrine therapy lines for MBC
0 50 (69%) 78 (96%)
1 17 (24%) 2 (2%)
2 5 (7%) 2 (2%)
Chemotherapy regimen received after inclusion
Taxane based 39 (48%)
Anthracycline based 29 (35%)
Other 14 (17%)
Endocrine therapy regimen received after inclusion
AI based 46 (64%)
Tamoxifen based 17 (24%)
Other 9 (12%)
CTC count at baseline
1-4 CTCs/7.5 ml 30 (42%) 24 (29%)
≥ 5 CTCs/7.5 ml 42 (58%) 58 (71%)
Follow-up, median days (range) 511 (30-1436) 406 (8-1430)No patients in either cohort received targeted therapies such as
trastuzumab or everolimus. Median follow-up of all patients was
15 months.
Incidence and Prognostic Value of HER2-Positive CTCs
Results regarding the prevalence of HER2-positive CTCs (2+ or 3+
staining) and their relation to the PFR6months are presented in
Table 2. HER2-positive CTCs were present in 19 patients receiving
endocrine treatment (26%) and in 26 patients receiving chemother-
apy (32%). The PFR6months in MBC patients treated with
endocrine therapy with at least one HER2-positive CTC was not
different from the PFR6months in patients without HER2-positive
CTCs (53% vs 68%, P = .23). When the analysis was restricted to
patients receiving first-line endocrine therapy, PFR6months did not
differ between patients with HER2-positive CTCs (n = 15, 60%)
versus patients without HER2-positive CTCs (n = 35, 71%; P =
.43). In the chemotherapy cohort, no difference in PFR6months
with regard to the HER2-CTC status was observed either (65% vs
57%, P = .48). In patients in whom HER2-positive CTCs were
present, the median HER2 to CTC ratio (total number of
HER2-positive CTCs divided by total number of CTCs) was 0.08
(Q1 0.03-Q3 0.22).
Because we had ample follow-up time for the included patients, we
also explored whether the presence of HER2-positive CTCs was
associated with PFS or OS in a univariate Cox regression model. The
presence of at least one HER2-positive CTC in the endocrine therapy
cohort was not associated with a difference in PFS [hazard ratio (HR)
1.17, 95% CI 0.65-2.09] or OS (1.72, 95% CI 0.73-4.03) (Figure 1,
A and C). Similarly, in the chemotherapy cohort, no association of
HER2-positive CTCs with change in PFS (HR 1.09, 95% CI
0.67-1.78) or OS (HR 0.93, 95% CI 0.53-1.63) was observed
(Figure 1, B and D).
When the cutoff for HER2 positivity was shifted to only the CTCs
that had a 3+ immunofluorescent staining, HER2-positive 3+ CTCs
were observed in 6 patients (8%) in the endocrine therapy cohort and
in 9 patients (11%) in the chemotherapy cohort. As the number of
patients with HER2-positive 3+ CTCs was very limited, we did not
perform formal statistics on differences in PFR6months.
Incidence and Prognostic Value of Switches in ER Status
Between PT and CTCs
The ER status of CTCs was assessed on the mRNA level and
determined using our predefined cutoff for ESR1 positivity as
described before [17]. We compared the ER status of the CTCs with
the ER status of the PT as reported by the pathologist. The ER-CTC
status could not be determined in 38 patients (25%): in 9 patients, no
sample for mRNA analysis was available; in 29 patients, the mRNA
was of poor quality or the epithelial mRNA signal was too low, the
latter being indicative of a CTC count too low for a reliable mRNATable 2. Prevalence and PRF6 Months in Relation to the HER2-CTC Status
Endocrine Therapy
(n = 72)
Chemotherapy
(n = 82)
HER2-positive CTCs (2+ or 3+ HER2 staining) present 19 (26%) 26 (32%)
HER2-positive CTCs (3+ HER2 staining) present 6 (8%) 9 (11%)
PFR 6 months
Absent HER2-positive CTCs (2+ or 3+ HER2 staining) 68% 57%
≥ 1 HER2-positive CTCs (2+ or 3+ HER2 staining) present 53% 65%
χ2 PFR 6 months P value (absent vs present) .23 .48
Figure 1. PFS and OS according to HER2-CTC status. (A and C) PFS and OS, respectively, for the endocrine therapy cohort. (B and D) PFS
and OS, respectively, for chemotherapy cohort.
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116 patients (75%) (Table 3). In the endocrine therapy cohort,
consisting solely of patients with ER-positive PTs, 10 patients (14%)
had ER-negative CTCs. In the chemotherapy cohort, 31% of the
patients had a discordant ER status between the PT and the CTCs.
Interestingly, out of 19 patients who had an ER-negative PT, 13
patients (68%) had ER-positive CTCs. In addition, in 7 out of
46 patients (15%) with an ER-positive PT, the CTCs were negative
for ER.
Exploratory Kaplan-Meier curves for the prognostic impact of ER
switches between the PT and the CTCs were constructed as planned.
As depicted in Figure 2, no clear prognostic impact of ER switch
appeared to be present in either the endocrine therapy cohort or the
chemotherapy cohort.Table 3. Discordances between Primary Tumor and CTC Regarding the ER Status
ESR1 Status CTCs Negative ESR1 Status CTCs Positive Total
Endocrine therapy
ER status primary tumor
Positive 10 41 51
Chemotherapy
ER status primary tumor
Negative 6 13 19
Positive 7 39 46
Total 13 52 65Associations Between HER2 and ER Status of CTCs and
the PT
We explored whether HER2-positive CTCs were related to the
HER2 HercepTest score as assessed on the PT by the pathologist in
the context of standard clinical care. For 42 patients, no data on the
PT HercepTest score were available. In the remaining 112 patients,
the HercepTest score (0, 1+, or 2+) was not found to be associated
with the presence or absence of HER2-positive CTCs (P = .24,
Supplementary Table 1). We also explored whether switches in
patients with an ER-positive PT to ER-negative CTCs were
associated with the percentage of ER-positive tumor cells in the
PT. Patients who had an ER-positive PT but ER-negative CTCs had
lower percentages of ER-positive tumor cells in the PT than patients
with an ER-positive PT in whom the CTCs remained ER positive
(P = .03; Supplementary Figure 2). No data on the percentage of
ER-positive tumor cells were available for patients with an
ER-negative PT.
Discussion
CTCs are an attractive alternative to solid biopsies and may give
insight into intratumor and intermetastatic heterogeneity [28,29].
Previous studies demonstrated discrepancies in the HER2 and ER
status between the PT and the metastases, as well as discordances of
these markers between the PT and the CTCs. However, appropriately
powered studies evaluating the prognostic impact of HER2-positive
CTCs have been scarce. We set out to evaluate the prevalence and
Figure 2. PFS and OS according to ER-CTC status. (A and C) PFS and OS, respectively, for the endocrine therapy cohort. (B and D) PFS and
OS, respectively, for chemotherapy cohort.
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HER2-negative PTs. We hypothesized that MBC patients with
HER2-positive CTCs would have a lower PFS after 6 months of
endocrine therapy compared with patients with HER2-negative
CTCs. Although discordance in the HER2 status between the PT and
CTCs was frequently present, no prognostic value of HER2-positive
CTCs was observed in MBC patients treated with endocrine therapy.
Our findings that HER2-positive CTCs occur in a relatively large
subset of HER2-negative MBC patients (45/154 patients, 29%) are
in accordance with previous reports. Wallwiener and colleagues [18]
used the same method as we did to score HER2-positive CTCs and
found HER2-positive CTCs in 30% of their 107 MBC patients with
≥5 CTCs and HER2-negative PTs. In contrast to our results, this
study observed that patients with ≥5 CTCs and HER2-positive CTCs
had a longer PFS than patients with ≥5 CTCs without HER2-positive
CTCs. However, because also patients with HER2-positive PTs who
were treated with HER2-targeted treatments were included in that
study, the results cannot directly be compared with our results.
Slightly higher numbers of HER2-positive CTCs than in our study
were observed by Fehm et al. [30], who used an immunofluorescent
staining on CellSearch for HER2 of 3+ and observed HER2-positive
CTCs in 25 of 76 (33%) MBC patients with HER2-negative PTs.
Although other studies have investigated the prognostic impact of
HER2-CTC status in MBC [4,8,12], either these studies did not use
an FDA-cleared method to enumerate CTCs followed by character-
ization for HER2 expression, or they did not sufficiently describetheir technique to score HER2-positive CTCs. For these reasons,
direct comparison of the results from these studies with our study is
not possible.
Although HER2-positive CTCs were frequently present in our
MBC patients, their presence was not of prognostic value. Our study
was powered to detect a 20% PFR6months in patients with
HER2-positive CTCs receiving endocrine therapy versus 70%
PFR6months in patients with HER2-negative CTCs, which was a
difference considered clinically relevant after a small survey among
medical oncologists. We believe that it is justified to have powered
this study for these sorts of large differences in PFR because only such
large differences will have a clear clinical impact and affect clinical
decision making. Our data at least suggest that the presence of
HER2-positive CTCs in patients with HER2-negative PTs does not
have a major impact on their prognosis. There are several explanations
for the lack of prognostic value of HER2-positive CTCs. First, it is
possible that there is indeed no association between HER2
overexpression in CTCs of MBC patients and outcome to endocrine
treatment. Second, specificity issues may have occurred when using
the CellSearch Tumor Phenotyping reagent HER2. We found a
moderate but significant correlation between the number of CTCs
and the number of HER2-positive CTCs (Spearman r = 0.31,
P b .001). This suggests that when a higher number of CTCs would
be present, there would be larger chance of finding at least one
HER2-positive CTC. This may be in line with the observed
heterogeneity for HER2 expression in CTCs as seen in the median
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of our study is that we did not perform fluorescence in situ
hybridization analysis on CTCs to confirm amplification of HER2,
which may have further improved the specificity of the HER2-CTC
assay. Fourth, a subset of patients in the endocrine therapy cohort had
already received prior endocrine therapy for MBC, which may have
impacted the analyses regarding PFS in this cohort. However, in a
subgroup analysis of patients receiving first-line endocrine therapy
which also met our power calculation, no prognostic value of
HER2-positive CTCs was observed either. Fifth, the fact that HER2
is overexpressed does not necessarily mean that it is also an active
driver of tumor growth in that particular patient. The determination
of phosphorylated HER2 or markers downstream of HER2 in CTCs
may provide better insight into the activity of the HER2 signaling
pathway in CTCs [31]. Lastly, there is currently no consensus on the
optimal cutoff for HER2 positivity. We chose CTCs immunofluor-
escently staining 2+ or 3+ as HER2 positive given that this was the
cutoff used in the CellSearch/Veridex interreader variability study
[32] and good agreement for this cutoff was demonstrated between
academic readers and Veridex consensus. However, other cutoffs for
HER2 positivity on CTCs might yield different results regarding the
prognostic impact of HER2-positive CTCs. Consensus on the
optimal cutoff for HER2-positive CTCs is needed and should be
driven by the prognostic power and clinical utility of such a cutoff (for
example, for response to anti-HER2 targeted agents).
With regard to ER status, we found discordance between the PT
and CTCs in 26% of our patients, which is in line with our previous
reports [9,17] and reports by others [6,13,33–35] describing
heterogeneity of CTCs for ER and discordances in ER status in
24% to 45% of the MBC cases. Especially of interest is that
ER-positive CTCs were observed in 68% of the patients with an
ER-negative PT, which might indicate that a subset of patients with
an ER-negative PT might benefit from endocrine therapy. Also worth
noting is the finding that in patients in whom the PT was ER positive
but the CTCs ER negative, the number of ER-positive tumor cells in
the primary was significantly lower than in patients in whom the
CTCs remained ER positive. This suggests that heterogeneity in ER
expression in the PT may give a higher chance of clonal evolution of
an ER-negative clone. Although heterogeneity and discordances
between PTs and CTCs for ER expression have frequently been
described, little is known about the prognostic impact of the
ER-CTC status. We previously explored the prognostic value of the
ER-CTC status and found patients with ER-negative PTs but
ER-positive CTCs to have a longer time-to-treatment-switch than
patients who remained ER negative [17]. However, in the present
study (comprising 30 of the patients who were also included in our
previous report), we were unable to confirm these findings. This
could be due to the facts that our previous cohort was smaller (n =
62) and that included patients were treated with either endocrine
therapy or chemotherapy. In addition, the applied cutoff for ER
positivity of CTCs in our previous study was based on ESR1 mRNA
levels in the PTs. Although this cutoff was demonstrated to have
excellent sensitivity and specificity [17], it was not feasible to validate
that cutoff value for the current study because the PT tissue was not
available for all patients. The exploratory analyses here indicating lack
of prognostic value should however be interpreted with caution, as the
number of patients who had a switch in ER status was limited. Larger
studies are required to evaluate the prognostic value of ER
discordances between the PT and CTCs, preferably also evaluatingER expression in CTCs at the single cell level to enable the evaluation
of heterogeneity in ER expression between single CTCs. We have
recently started a study in which we are evaluating heterogeneity of
ER-positive CTCs and their prognostic impact using a proximity
ligation assay technique (CareMore-Trastuzumab study and
CareMore-AI study; NTR5121 [36,37]), whereas others have
reported on immunofluorescent ER staining directly in the
CellSearch machine, similar to HER2 in this study [35].
In conclusion, a lack of prognostic value was observed for
HER2-positive CTCs and ER-positive CTCs with respect to outcome
to endocrine therapy or chemotherapy in MBC patients. Future
research should focus on ER characterization of CTCs in a larger patient
cohort but may also focus on looking beyond classical predictive factors
(such as HER2 and ER expression) that are related to endocrine
resistance. This could for example be done by determining resistant
mutations in ESR1 [34] or measuring gene expression panels associated
with resistance to antitumor therapy [23,24]. Such characterization of
several prognostic and predictive markers on CTCs correlated with
resistance to either endocrine therapy or chemotherapy may eventually
lead to improved prognostication and prediction of therapeutic
response in MBC patients.
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